Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SRPT Stock Forecast 2025-2026
$21.56
Current Price
$2.12B
Market Cap
Buy 14
Hold 11
Sell 1
Wall St Analyst Ratings
Distance to SRPT Price Targets
+410.2%
To High Target of $110.00
+85.5%
To Median Target of $40.00
-53.6%
To Low Target of $10.00
SRPT Price Momentum
-42.2%
1 Week Change
-43.2%
1 Month Change
-81.7%
1 Year Change
-82.3%
Year-to-Date Change
-87.6%
From 52W High of $173.25
+17.8%
From 52W Low of $18.30
📊 TOP ANALYST CALLS
Did SRPT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Sarepta is one of their latest high-conviction picks.
Latest SRPT Stock Price Targets & Analyst Predictions
Based on our analysis of 39 Wall Street analysts, SRPT has a bullish consensus with a median price target of $40.00 (ranging from $10.00 to $110.00). The overall analyst rating is Buy (7.8/10). Currently trading at $21.56, the median forecast implies a 85.5% upside. This outlook is supported by 14 Buy, 11 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Biren Amin at Piper Sandler, projecting a 410.2% upside. Conversely, the most conservative target is provided by Mitchell Kapoor at HC Wainwright & Co., suggesting a 53.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SRPT Analyst Ratings
14
Buy
11
Hold
1
Sell
SRPT Price Target Range
Low
$10.00
Average
$40.00
High
$110.00
Current: $21.56
Latest SRPT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SRPT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 17, 2025 | Deutsche Bank | David Hoang | Hold | Maintains | $25.00 |
| Jun 17, 2025 | Goldman Sachs | Salveen Richter | Neutral | Downgrade | $29.00 |
| Jun 17, 2025 | Baird | Brian Skorney | Outperform | Maintains | $30.00 |
| Jun 17, 2025 | Morgan Stanley | Matthew Harrison | Equal-Weight | Downgrade | $40.00 |
| Jun 17, 2025 | Barclays | Gena Wang | Overweight | Maintains | $29.00 |
| Jun 17, 2025 | Wolfe Research | Andy Chen | Peer Perform | Initiates | $0.00 |
| Jun 17, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $75.00 |
| Jun 16, 2025 | Piper Sandler | Biren Amin | Neutral | Downgrade | $36.00 |
| Jun 16, 2025 | Jefferies | Andrew Tsai | Buy | Maintains | $54.00 |
| Jun 16, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Sell | Downgrade | $10.00 |
| Jun 16, 2025 | B of A Securities | Tazeen Ahmad | Neutral | Downgrade | $28.00 |
| Jun 16, 2025 | Needham | Gil Blum | Buy | Maintains | $50.00 |
| Jun 16, 2025 | BMO Capital | Kostas Biliouris | Market Perform | Downgrade | $70.00 |
| Jun 6, 2025 | Scotiabank | Louise Chen | Sector Outperform | Upgrade | $80.00 |
| May 22, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $40.00 |
| May 20, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $84.00 |
| May 8, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $100.00 |
| May 7, 2025 | Oppenheimer | Hartaj Singh | Outperform | Maintains | $123.00 |
| May 7, 2025 | Goldman Sachs | Salveen Richter | Buy | Maintains | $100.00 |
| May 7, 2025 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $98.00 |
Sarepta Therapeutics Inc. (SRPT) Competitors
The following stocks are similar to Sarepta based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sarepta Therapeutics Inc. (SRPT) Financial Data
Sarepta Therapeutics Inc. has a market capitalization of $2.12B with a P/E ratio of 20.0x. The company generates $2.23B in trailing twelve-month revenue with a -11.1% profit margin.
Revenue growth is +80.2% quarter-over-quarter, while maintaining an operating margin of -40.3% and return on equity of -23.6%.
Valuation Metrics
Market Cap
$2.12B
Enterprise Value
$2.95B
P/E Ratio
20.0x
PEG Ratio
1.9x
Price/Sales
0.9x
Growth & Margins
Revenue Growth (YoY)
+80.2%
Gross Margin
+81.5%
Operating Margin
-40.3%
Net Margin
-11.1%
EPS Growth
+80.2%
Financial Health
Cash/Price Ratio
+24.7%
Current Ratio
4.0x
Debt/Equity
118.7x
ROE
-23.6%
ROA
-2.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Sarepta Therapeutics Inc. (SRPT) Business Model
About Sarepta Therapeutics Inc.
What They Do
Develops genetic medicine for rare neuromuscular diseases.
Business Model
Sarepta Therapeutics generates revenue by developing and commercializing innovative therapies for rare diseases, particularly through partnerships and collaborations with healthcare providers and academic institutions. The company focuses on RNA-targeted therapeutics to treat Duchenne muscular dystrophy (DMD), aiming to provide solutions that address the genetic causes of such conditions.
Additional Information
Sarepta is at the cutting edge of genetic medicine, with a strong emphasis on research and development. Its advanced bioinformatics capabilities enhance drug discovery processes, positioning the company as a leader in the biopharmaceutical sector and potentially transforming patient care in rare diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1,372
CEO
Mr. Douglas S. Ingram Esq.
Country
United States
IPO Year
1997
Website
www.sarepta.comSarepta Therapeutics Inc. (SRPT) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Company News for Jun 17, 2025
Companies in The News Are: RNW, NOC, SRPT, AMD.
Jun 17, 2025
By Zacks Equity Research
Corporate Summary
Latest News
Quick Summary
Sarepta Therapeutics reported a second case of acute liver failure resulting in death following its gene therapy treatment for muscular dystrophy.
Why It Matters
The report of a second acute liver failure case linked to Sarepta's gene therapy raises serious safety concerns, potentially impacting stock performance and investor confidence in the company.
Source: Reuters
Market Sentiment:
Negative
Quick Summary
CNBC reports on new developments concerning Sarepta, providing updates that may impact investor interest and market performance.
Why It Matters
Sarepta's updates can significantly impact stock performance, reflecting investor sentiment and potential market movements related to its therapies or financial health.
Source: CNBC Television
Market Sentiment:
Negative
Quick Summary
Sarepta Therapeutics shares dropped 34% in premarket trading following the disclosure of a second patient death from acute liver failure linked to its gene therapy for muscular dystrophy.
Why It Matters
The sharp decline in Sarepta Therapeutics' shares indicates heightened investor concern over safety issues, potentially impacting future sales and regulatory scrutiny for its gene therapy.
Source: Reuters
Market Sentiment:
Negative
Quick Summary
Sarepta's stock fell sharply after the announcement of a second patient death linked to its gene therapy, Elevidys.
Why It Matters
Sarepta's stock drop signals heightened risk and concerns over the safety of its gene therapy, potentially impacting investor confidence and future funding opportunities.
Source: Investors Business Daily
Market Sentiment:
Negative
Quick Summary
Sarepta Therapeutics (NASDAQ:SRPT) shares fell nearly 45% after a second patient died from liver failure linked to its gene therapy Elevidys. The company will form a panel to improve safety protocols, pending FDA review.
Why It Matters
The sharp decline in Sarepta's stock reflects heightened risk perception and regulatory uncertainty surrounding its gene therapy, impacting investor confidence and potential future revenues.
Source: Proactive Investors
Market Sentiment:
Negative
Quick Summary
Kehoe Law Firm is investigating potential federal securities law violations involving Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on behalf of its investors.
Why It Matters
Sarepta Therapeutics may face legal issues regarding federal securities laws, potentially impacting its stock value and investors' returns.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About SRPT Stock
What is Sarepta Therapeutics Inc.'s (SRPT) stock forecast for 2025?
Based on our analysis of 39 Wall Street analysts, Sarepta Therapeutics Inc. (SRPT) has a median price target of $40.00. The highest price target is $110.00 and the lowest is $10.00.
Is SRPT stock a good investment in 2025?
According to current analyst ratings, SRPT has 14 Buy ratings, 11 Hold ratings, and 1 Sell ratings. The stock is currently trading at $21.56. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SRPT stock?
Wall Street analysts predict SRPT stock could reach $40.00 in the next 12 months. This represents a 85.5% increase from the current price of $21.56. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sarepta Therapeutics Inc.'s business model?
Sarepta Therapeutics generates revenue by developing and commercializing innovative therapies for rare diseases, particularly through partnerships and collaborations with healthcare providers and academic institutions. The company focuses on RNA-targeted therapeutics to treat Duchenne muscular dystrophy (DMD), aiming to provide solutions that address the genetic causes of such conditions.
What is the highest forecasted price for SRPT Sarepta Therapeutics Inc.?
The highest price target for SRPT is $110.00 from Biren Amin at Piper Sandler, which represents a 410.2% increase from the current price of $21.56.
What is the lowest forecasted price for SRPT Sarepta Therapeutics Inc.?
The lowest price target for SRPT is $10.00 from Mitchell Kapoor at HC Wainwright & Co., which represents a -53.6% decrease from the current price of $21.56.
What is the overall SRPT consensus from analysts for Sarepta Therapeutics Inc.?
The overall analyst consensus for SRPT is bullish. Out of 39 Wall Street analysts, 14 rate it as Buy, 11 as Hold, and 1 as Sell, with a median price target of $40.00.
How accurate are SRPT stock price projections?
Stock price projections, including those for Sarepta Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 18, 2025 4:49 PM UTC